EPO to Hear Mirrx Request for Resumption of Patent Proceedings Covering miRNA Rx Technology

As part of a lawsuit seeking control of the technology, Santaris has successfully petitioned the European Patent Office to stay its review of Mirrx's patent application.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.